Fact-checked by Grok 2 weeks ago

PET–CT

PET–CT, or positron emission tomography–computed tomography, is a hybrid nuclear medicine imaging technique that integrates the metabolic and functional information from positron emission tomography (PET) with the high-resolution anatomical details from computed tomography (CT).^[1] This combination allows for precise localization of abnormalities by overlaying functional data on structural images, enabling clinicians to detect and characterize diseases such as cancer at an early stage.^[2] Developed in the late 1990s and widely adopted since the early 2000s, PET–CT scanners perform nearly all modern PET scans, providing attenuation correction and fused images that enhance diagnostic accuracy.^[3] In a typical PET–CT procedure, a patient receives an intravenous injection of a radiotracer, most commonly fluorodeoxyglucose (FDG) labeled with fluorine-18, which accumulates in tissues with high metabolic activity, such as cancer cells that exhibit enhanced glucose utilization compared to normal cells.^[2] After a waiting period of 30 to 60 minutes for the tracer to distribute, the patient lies on a table that moves through the combined PET–CT scanner; the CT component, using X-rays, takes less than two minutes to produce cross-sectional anatomical images, followed by the PET scan, which lasts 20 to 30 minutes to capture gamma rays from positron-electron annihilation events.^[1] The entire process usually spans about two hours and is performed on an outpatient basis, requiring the patient to remain still to avoid motion artifacts.^[4] PET–CT is primarily used in oncology for staging, restaging, and monitoring the response to treatment in various cancers, including lung, colorectal, breast, lymphoma, and head and neck malignancies, by identifying areas of increased metabolic activity that may indicate tumors or metastases.^[3] Beyond cancer, it evaluates cardiac conditions like myocardial viability and perfusion, and neurological disorders such as Alzheimer's disease, epilepsy, and brain tumors, where it can reveal biochemical changes before structural alterations become evident on other imaging modalities.^[4] The technique's ability to provide both functional and anatomical insights makes it invaluable for guiding biopsies, radiation therapy planning, and assessing treatment efficacy.^[2] While PET–CT offers significant benefits, including early disease detection, non-invasiveness, and improved diagnostic precision over standalone PET or CT, it involves exposure to ionizing radiation from both the radiotracer and CT scan, though the effective dose is typically 20-25 mSv, equivalent to about 200-250 chest X-rays or roughly 7 years of natural background radiation.^[1]^[5] Risks are minimal, including rare allergic reactions to the tracer or discomfort from injection, but it is contraindicated for pregnant individuals due to fetal radiation exposure; additionally, high blood sugar levels can interfere with FDG uptake, and the procedure may not be suitable for very obese patients due to scanner limitations.^[2] Overall, PET–CT represents a cornerstone of modern diagnostic imaging, revolutionizing the management of metabolic and oncologic conditions.^[3]

Overview

Definition and Purpose

PET–CT, also known as positron emission tomography–computed tomography, is a hybrid medical imaging modality that combines the functional imaging capabilities of positron emission tomography (PET) with the anatomical detail provided by computed tomography (CT) in a single, simultaneous scanning procedure.^[6] This integration allows for the acquisition of co-registered images where metabolic activity, detected through positron-emitting radiotracers administered to the patient, is overlaid onto high-resolution structural images generated via X-ray attenuation. The result is a comprehensive visualization that addresses the shortcomings of standalone modalities: PET alone provides limited anatomical localization due to its lower spatial resolution, while CT excels in morphology but offers no insight into physiological or biochemical processes.^[1] The primary purpose of PET–CT is to enhance diagnostic accuracy by correlating metabolic or functional abnormalities with precise anatomical locations, facilitating the detection, staging, and monitoring of conditions such as oncology, cardiology, and neurology-related diseases, including tumors, ischemia, and inflammation.^[6] For instance, it enables clinicians to identify hypermetabolic lesions and their exact positions within organs, improving treatment planning and prognostic assessment compared to separate PET and CT scans.^[1] This hybrid approach emerged in the early 2000s to overcome the practical challenges of manually fusing images from independent scanners, which often led to misalignment and reduced clinical utility. Commonly used radiotracers in PET–CT include positron-emitting isotopes such as fluorine-18 (^18F), with 18F-fluorodeoxyglucose (FDG) serving as the primary agent due to its ability to mimic glucose and accumulate in tissues with elevated metabolic rates, such as malignant cells.^[1] Other isotopes like carbon-11 (^11C), nitrogen-13 (^13N), and oxygen-15 (^15O) may be employed for specific applications, but FDG remains the most widely adopted for its favorable half-life and imaging properties.^[1]

Basic Principles

Positron emission tomography (PET) relies on the detection of gamma rays produced by the annihilation of positrons emitted from radionuclides incorporated into biological tracers. When a positron-emitting radionuclide decays, it releases a positron that travels a short distance before annihilating with an electron, producing two photons each with an energy of 511 keV that travel in nearly opposite directions.^[7] These photons are detected in coincidence by a ring of detectors surrounding the patient, meaning only events where both photons are registered almost simultaneously (within a narrow time window, typically nanoseconds) are accepted to minimize random coincidences and background noise.^[8] This coincidence detection localizes the annihilation event along a line of response (LOR), defined mathematically as the straight line connecting the positions of the two detecting crystals, \vec{r} = (1 - \lambda) \vec{d_1} + \lambda \vec{d_2} where \vec{d_1} and \vec{d_2} are the detector positions and \lambda \in [0,1].^[9] The spatial resolution of PET is inherently limited by factors such as the positron range—the distance the positron travels before annihilation, which varies by isotope (e.g., up to several millimeters for common tracers like fluorine-18)—and acolinearity, where the photons deviate from exact 180° opposition by about 0.25° due to the center-of-mass motion of the annihilating particles, contributing to a typical system resolution of 4-6 mm.^[10] Computed tomography (CT) in PET–CT systems provides anatomical context through X-ray attenuation mapping. CT scanners emit a fan-shaped beam of X-rays that pass through the body, with detectors measuring the transmitted intensity to quantify tissue density based on the linear attenuation coefficient \mu, which describes how much the X-ray beam is weakened per unit length.^[11] The resulting images are reconstructed into a density map using Hounsfield units (HU), a standardized scale where water is 0 HU, air is -1000 HU, and bone is around +1000 HU, enabling precise differentiation of soft tissues, bones, and air-filled structures.^[12] This attenuation data is crucial for correcting PET signals, as gamma rays from positron annihilation are similarly attenuated by body tissues, following the exponential law I = I_0 e^{-\int \mu ds} along the photon path, where uncorrected PET images would underestimate activity in deeper regions.^[13] The synergy of PET and CT in hybrid systems arises from co-registering functional PET data, which quantifies metabolic activity via metrics like the standardized uptake value (SUV)—defined as SUV = (tissue concentration in Bq/mL) / (injected dose in Bq / body weight in kg)—with CT's high-resolution anatomical images acquired sequentially in the same scan session.^[14] This fusion allows CT-derived attenuation maps to correct PET data for photon absorption, significantly improving the quantitative accuracy of SUV measurements, while also enabling precise localization of functional abnormalities (e.g., hypermetabolic lesions) onto anatomical structures without relying on separate imaging modalities.^[15] The integrated design minimizes patient motion artifacts and ensures spatial alignment, enhancing overall diagnostic precision.^[16]

History

Early Development of PET and CT

The development of computed tomography (CT) began with pioneering work in the early 1970s, when British engineer Godfrey Hounsfield constructed the first prototype X-ray tomography scanner at EMI Laboratories. This device, completed in 1971, used a translate-rotate geometry with a pencil beam to acquire cross-sectional images, marking the birth of CT as a revolutionary imaging modality. Hounsfield's innovation, shared with physicist Allan Cormack who developed the underlying mathematical reconstruction algorithms, earned them the Nobel Prize in Physiology or Medicine in 1979. The first clinical CT scan on a human patient occurred on October 1, 1971, at Atkinson Morley's Hospital in London, demonstrating a brain cyst and establishing CT's potential for non-invasive anatomical visualization. Over the subsequent decades, CT technology evolved rapidly. The introduction of helical (spiral) scanning in the early 1990s enabled continuous data acquisition during patient movement through the gantry, improving speed and reducing motion artifacts. By the late 1990s, multi-slice CT scanners with multiple detector rows—first commercialized around 1998—further advanced the technology, allowing simultaneous acquisition of multiple image slices for faster, higher-resolution volumetric imaging. These developments solidified CT as the standard modality for detailed anatomical assessment in clinical practice by the 1990s, widely adopted for diagnostics in neurology, oncology, and beyond due to its enhanced efficiency and image quality. Positron emission tomography (PET) originated in the mid-20th century with early positron imaging experiments. In the 1950s, physicist Gordon Brownell at the Massachusetts General Hospital developed the first cyclotron-based positron detector using sodium iodide crystals, in collaboration with neurosurgeon William Sweet, to image brain tumors in humans. This device laid the groundwork for functional imaging by detecting annihilation photons from positron-emitting radionuclides. In 1961, James Robertson et al. at Brookhaven National Laboratory built the first single-plane PET scanner, nicknamed the "head-shrinker"^[17]. Significant progress occurred in the 1970s at Washington University School of Medicine, where Michael E. Phelps, along with Michel M. Ter-Pogossian and Edward J. Hoffman, designed and built the first human PET scanner in 1973, featuring an array of detectors for tomographic reconstruction. Key milestones in PET included the acquisition of the first PET image of a human brain in 1975, using an improved scanner with hexagonal detectors that enhanced resolution and sensitivity. During this period, ring-shaped and cylindrical detector systems, such as the PET Camera-I (PC-I) reported in 1972 and later models, enabled quantitative functional imaging of metabolism and physiology. During the 1980s, PET transitioned toward clinical utility with further refinements in detector systems. However, widespread clinical adoption remained limited in the 1980s due to the high costs of on-site cyclotrons for short-lived radiotracer production and the overall expense of scanner infrastructure, confining PET primarily to research settings. By the 1990s, advancements in radiopharmaceuticals like 18F-FDG facilitated broader research applications, particularly in oncology and neurology. A persistent challenge in standalone PET imaging was its limited spatial resolution for precise anatomical localization of functional abnormalities, as PET primarily depicted metabolic activity without clear structural context. This limitation became increasingly evident in the late 1990s, prompting conceptual publications that highlighted the need for co-registration with high-resolution anatomical modalities like CT to improve diagnostic accuracy.

Emergence of Hybrid PET–CT Systems

The emergence of hybrid PET–CT systems began with the conceptual development led by physicist David Townsend and engineer Ronald Nutt at the University of Pittsburgh in the early 1990s, where they envisioned integrating positron emission tomography (PET) for functional imaging with computed tomography (CT) for anatomical detail to overcome limitations in aligning separate scans. This idea culminated in the construction of the first PET–CT prototype in 1998 by CTI PET Systems (now part of Siemens Molecular Imaging), featuring a modified single-slice spiral CT scanner coupled with a partial-ring PET detector; the prototype was installed and clinically evaluated at the University of Pittsburgh Medical Center from 1998 to 2001, demonstrating improved lesion localization in oncology patients through coregistered images.^[18]^[19] The transition to clinical use accelerated with Siemens unveiling the first commercial PET–CT scanner, the Biograph, at the Radiological Society of North America (RSNA) meeting in 2000, which received FDA clearance in 2001; this system combined a multislice CT with a full-ring PET detector, enabling simultaneous acquisition and fusion in a single session. Adoption surged rapidly, with over 1,000 PET–CT systems installed worldwide by 2005, driven by their superior diagnostic accuracy in staging and restaging cancers compared to standalone modalities. A pivotal milestone came in 2005 when the U.S. Centers for Medicare & Medicaid Services (CMS) expanded reimbursement coverage for PET scans, including hybrid systems, for various oncologic indications effective January 28, 2005, significantly boosting clinical utilization across the United States.^[20]^[21]^[22] By the 2010s, hybrid PET–CT technology evolved to incorporate time-of-flight (TOF) capabilities, first commercially introduced around 2007 and widely adopted by 2015, enhancing image quality and signal-to-noise ratios through precise timing of photon detection, which reduced artifacts in larger patients and supported faster scans. This integration shortened overall examination times from 30–60 minutes for sequential PET and CT procedures to 20–30 minutes for hybrid systems, improving patient throughput and comfort while maintaining diagnostic efficacy. Globally, installations reached approximately 2,500 PET–CT scanners by 2020, reflecting sustained growth in clinical demand for molecular-anatomical imaging.^[23]^[24]^[25]

Technical Components

Positron Emission Tomography Mechanism

Positron emission tomography (PET) relies on the administration of radiotracers containing positron-emitting isotopes, typically produced in a cyclotron. These isotopes, such as fluorine-18 (¹⁸F) with a half-life of approximately 110 minutes, undergo beta-plus decay, emitting a positron that travels a short distance in tissue before annihilating with an electron.^[3] This annihilation produces two gamma photons, each with an energy of 511 keV, emitted in nearly opposite directions (180° apart), which forms the basis for imaging metabolic processes.^[3] The detection system in a PET scanner consists of an array of scintillation crystals arranged in a ring around the patient, commonly using lutetium oxyorthosilicate (LSO) or bismuth germanate (BGO). These crystals absorb the 511 keV photons and convert them into visible light flashes, which are then amplified by photomultiplier tubes (PMTs) to generate electrical signals.^[3] The ring configuration allows for simultaneous detection from multiple angles, enabling the localization of the annihilation events along lines of response (LORs).^[26] Coincidence detection circuitry identifies valid annihilation events by requiring two opposing detectors to register photons within a narrow timing window of 6-12 nanoseconds, rejecting random coincidences that occur outside this period.^[3] Modern PET systems often operate in a septa-less 3D acquisition mode, which removes inter-ring septa to increase sensitivity by capturing oblique LORs, though this necessitates advanced scatter and random event corrections.^[26] Image formation begins with the projection of coincidence data into a sinogram, followed by corrections for attenuation, scatter, and dead time. Reconstruction algorithms then generate quantitative images, with filtered back-projection (FBP) providing a straightforward analytical approach and iterative methods like ordered subset expectation maximization (OSEM) offering improved noise reduction and convergence for clinical use.^[3]^[26] A key quantitative metric in PET is the standardized uptake value (SUV), which normalizes tracer uptake to account for administered dose and patient size. The SUV is calculated as:

\text{SUV} = \frac{\text{activity concentration (e.g., kBq/mL)}}{\text{injected dose (kBq) / body weight (g)}}

assuming a tissue density of 1 g/mL, enabling semi-quantitative assessment of metabolic activity.^[27]

Computed Tomography Integration

The computed tomography (CT) component in PET–CT systems consists of a rotating X-ray tube and a multi-row detector array configured in a multi-slice setup, typically ranging from 16 to 128 slices per rotation to enable rapid volumetric imaging.^[28] This hardware employs fan-beam geometry, where the X-ray beam diverges in a fan shape from the tube to the curved detector array, facilitating helical scanning for efficient coverage of large anatomical regions.^[29] A primary role of the integrated CT is to generate attenuation maps (μ-maps) comprising linear attenuation coefficients (μ) at 511 keV, derived by scaling CT Hounsfield units through bilinear transformation to correct for photon attenuation and scatter in PET data.^[30] These μ-maps enable quantitative PET reconstruction by applying the attenuation correction formula, where the corrected PET signal along a line of response is obtained as:

\text{Corrected PET} = \frac{\text{PET}_\text{raw}}{\exp\left( -\int \mu \, ds \right)}

with the integral representing the cumulative attenuation along the photon path ds.^[30] This process improves PET accuracy by compensating for tissue-dependent photon loss, particularly in dense structures like bone. To balance anatomical detail with radiation minimization, PET–CT employs low-dose CT protocols, typically operating at 50–100 mAs tube current, which reduces the effective dose by 30–50% compared to diagnostic CT while preserving sufficient contrast for μ-map generation and localization.^[31] Scanning synchronization ensures precise co-registration between CT and PET datasets, achieved through sequential acquisition—often a helical CT scan followed by stepwise PET bed positions—or interleaved modes, with the patient table aligning both modalities axially to avoid motion-induced misalignment.^[32] Common CT artifacts in hybrid PET–CT include beam hardening, which manifests as streak or cupping distortions due to polychromatic X-ray beam penetration through high-density tissues, potentially biasing μ-maps and PET quantification.^[33] Partial volume effects arise when thin structures straddle voxel boundaries, leading to averaged attenuation coefficients that underestimate μ in small lesions and propagate errors to corrected PET images.^[34]

Image Acquisition and Fusion

In PET–CT systems, image acquisition proceeds sequentially, with the computed tomography (CT) scan collected first, followed by positron emission tomography (PET) data acquisition. The CT serves dual purposes: providing anatomical detail and enabling attenuation correction for the PET data. This process can utilize either a diagnostic-quality CT for high-resolution anatomy or a low-dose CT optimized for attenuation mapping to minimize radiation exposure. The total scan duration for a standard whole-body examination typically ranges from 15 to 30 minutes, encompassing multiple bed positions to cover the region from skull base to mid-thighs.^[35]^[36] Following acquisition, computational fusion aligns the PET and CT datasets to integrate functional and anatomical information. Fusion algorithms commonly apply rigid registration for scenarios with minimal deformation or deformable registration to accommodate soft-tissue motion, employing mutual information metrics to quantify and optimize image similarity by maximizing shared statistical dependencies between modalities. These processes are implemented in proprietary software suites, such as Siemens syngo for multimodality fusion and GE Advantage for integrated PET–CT analysis, ensuring accurate co-registration even in complex anatomies.^[37]^[38]^[39] The reconstruction pipeline leverages CT-derived attenuation maps to guide iterative algorithms in PET image formation, such as ordered subset expectation maximization (OSEM), which iteratively refines estimates to suppress noise and enhance lesion contrast. This CT-guided approach typically achieves 20–30% noise reduction relative to non-iterative filtered back-projection, improving signal-to-noise ratios while preserving quantitative accuracy in uptake measurements.^[40]^[41] Quality control measures in PET–CT acquisition address physiological motion, particularly respiratory effects, through 4D techniques that incorporate time-resolved data for gating and correction. Respiratory gating synchronizes image bins to breathing phases, reducing blurring and enabling motion-compensated reconstruction, while the combined system's spatial resolution is limited to approximately 5 mm due to positron range, non-colinearity, and detector geometry.^[42]^[43] Fused PET–CT outputs are formatted for clinical interpretation as color overlays, superimposing PET metabolic activity—rendered in hot (high uptake) or cold (low uptake) scales—onto grayscale CT structures to highlight functional-anatomical correlations, such as tumor localization relative to vessels or organs.^[44]^[45]

Clinical Procedure

Patient Preparation and Safety

Patient preparation for PET–CT imaging is essential to ensure image quality and minimize physiological interferences, particularly with the commonly used radiotracer 18F-fluorodeoxyglucose (FDG). Patients are typically required to fast for 4–6 hours prior to the scan to reduce blood glucose levels, as elevated glucose can compete with FDG uptake in tissues and degrade diagnostic accuracy.^[46] During this period, only water is permitted, with recommendations to consume 1–2 liters to promote hydration and facilitate urinary excretion of unbound tracer post-injection.^[47] Additionally, patients should avoid caffeine, alcohol, and nicotine for at least 12 hours beforehand to prevent alterations in metabolic activity that could affect tracer distribution.^[48] Following preparation, the FDG tracer is administered intravenously in doses ranging from 5–15 mCi (approximately 185–555 MBq), tailored to body weight and scanner sensitivity to optimize signal while adhering to radiation safety standards.^[49] After injection, patients undergo a 60-minute uptake phase in a quiet, warm room to minimize muscle uptake from physical activity or stress, ensuring the tracer accumulates primarily in metabolically active tissues.^[41] Safety protocols emphasize screening for pregnancy, as FDG crosses the placenta and could expose the fetus to radiation; women of childbearing potential must confirm non-pregnancy via history or testing, with alternative imaging considered if necessary.^[50] Contraindications include uncontrolled diabetes, where hyperglycemia may necessitate rescheduling or specialized protocols like insulin management to achieve blood glucose below 200 mg/dL.^[51] The ALARA (as low as reasonably achievable) principle guides all procedures to limit radiation exposure through optimized dosing and shielding. The effective radiation dose from a typical whole-body PET–CT scan ranges from 10–25 mSv, comprising approximately 7–14 mSv from the PET component and 3–10 mSv from the CT, which is comparable to 3–8 years of natural background radiation (about 3 mSv annually).^[52] Informed consent is obtained prior to the procedure, discussing potential risks such as rare allergic reactions to the tracer (incidence <0.1%) or claustrophobia during the enclosed scan, though these are mitigated with monitoring and anxiolytics if needed.^[53]

Imaging Process and Protocols

The imaging process for PET–CT begins with the patient positioned supine on the scanner table, typically with arms elevated above the head to minimize attenuation artifacts and ensure consistent imaging, though arms may be positioned alongside the body for head, neck, or brain scans to avoid discomfort or contraindications such as recent surgery or injury.^[41] Immobilization devices, such as straps or cushions, are often used to maintain this position throughout the acquisition for reproducibility.^[54] The standard scan sequence for whole-body PET–CT, covering from the skull base to mid-thighs, initiates with a low-dose scout CT (topogram) to define the scan range and plan bed positions, followed by a low-dose CT for attenuation correction (typically 30–60 seconds), and then the PET emission acquisition in stepwise bed positions (2–5 minutes per position, with 30–50% overlap between positions to reduce artifacts).^[41]^[55] In diagnostic modes, a higher-dose contrast-enhanced CT may follow the PET emission to provide detailed anatomical correlation.^[41] Protocol variations depend on the clinical indication; for oncology with FDG, a common whole-body protocol uses approximately 1 minute per bed position adjusted for patient weight (e.g., administered activity of 14 MBq·min·bed⁻¹·kg⁻¹ with ≤30% overlap), emphasizing uniform coverage for tumor detection.^[41] Specialized protocols, such as rubidium-82 (Rb-82) for cardiac perfusion, involve dynamic PET acquisitions at rest and stress (e.g., adenosine infusion), with shorter bed times (1–2 minutes) focused on the heart and often including ECG gating to synchronize with cardiac cycles for motion-free imaging.^[56]^[57] During acquisition, physiological monitoring is integrated as needed; ECG leads are applied for cardiac gating in perfusion studies to correct for heartbeat-induced motion, while respiratory bellows or belts track breathing for gating in thoracic or abdominal scans to mitigate motion blur in lung or liver regions.^[57]^[58] Intravenous contrast may be administered if the CT component is diagnostic, enhancing vascular and lesion visibility.^[41] The total scan duration is typically 30–45 minutes for whole-body oncology protocols, or around 30 minutes for cardiac studies, with patients instructed to remain as still as possible, breathe normally or shallowly during CT, and void the bladder if needed post-scan for comfort and to reduce radiation exposure.^[41]^[56]

Applications

Oncology Uses

PET–CT plays a pivotal role in oncology by leveraging the metabolic activity detected by positron emission tomography (PET) with the anatomical detail provided by computed tomography (CT), enabling precise identification and characterization of tumors. This hybrid imaging modality is particularly valuable for detecting metabolically active malignancies, as most cancer cells exhibit increased glucose uptake compared to normal tissues, which is quantified using fluorodeoxyglucose (FDG). In clinical practice, PET–CT enhances diagnostic accuracy across various stages of cancer management, from initial detection to monitoring therapeutic efficacy.^[59] For tumor detection, PET–CT demonstrates high sensitivity for identifying metabolically active lesions, often outperforming CT alone, especially in cases where anatomical imaging may miss small or non-obstructive tumors. In non-small cell lung cancer (NSCLC), for instance, integrated FDG PET–CT achieves a sensitivity of over 95% for detecting primary tumors and 70-90% for nodal involvement, compared to 60-70% for CT alone in nodal staging, due to its ability to highlight hypermetabolic regions irrespective of size or location.^[60]^[61] This is particularly useful in screening high-risk populations or evaluating solitary pulmonary nodules, where PET–CT reduces unnecessary biopsies by distinguishing benign from malignant processes with greater specificity. However, detection relies on sufficient tumor FDG avidity, limiting utility in low-uptake cancers like certain neuroendocrine tumors. In cancer staging, PET–CT excels at assessing lymph node involvement and distant metastases, integrating functional and structural data to refine TNM classification with anatomical precision. It improves accuracy for N-staging in colorectal cancer by detecting lymph node metastases with a sensitivity of 67% (95% CI: 62-71%), surpassing CT's 55% (95% CI: 51-60%), and aids in identifying occult distant sites, altering management in up to 20-30% of cases.^[62] For M-staging, PET–CT identifies extrathoracic metastases in NSCLC with a sensitivity of 85-93%, enabling more accurate prognostication and treatment planning, such as avoiding futile surgeries. This combined approach minimizes staging errors that could lead to inappropriate therapies.^[63] Monitoring therapy response with PET–CT involves evaluating changes in standardized uptake value (SUV), which complements RECIST criteria by capturing metabolic shifts earlier than size-based assessments alone. A decrease in SUVmax of greater than 25-30% after chemotherapy often indicates a favorable response, correlating with improved progression-free survival in lymphomas and solid tumors, as per PERCIST guidelines. For example, in NSCLC post-chemoradiation, an SUV decline exceeding 25% predicts pathological response with 80-90% accuracy, guiding decisions on continuing or switching regimens. This metabolic insight allows for interim assessments during treatment, potentially sparing non-responders from ineffective therapies.^[64]^[65] PET–CT is routinely applied in common cancers such as lung, colorectal, and lymphoma, where it informs diagnosis, staging, and restaging. In lung cancer, it detects occult metastases missed by conventional imaging; in colorectal cancer, it evaluates hepatic and nodal spread; and in lymphoma, it assesses disease extent using Deauville criteria for FDG uptake. False positives can occur due to inflammatory conditions, such as sarcoidosis mimicking lymphoma with intense FDG avidity in lymph nodes, necessitating correlation with clinical history and biopsy in ambiguous cases. These pitfalls highlight the importance of interpreting results in context to avoid overstaging.^[66]^[67]^[68] Quantitative tools like metabolic tumor volume (MTV) and total lesion glycolysis (TLG), derived from PET–CT, provide prognostic insights beyond SUV by measuring overall tumor burden and glycolytic activity. Thresholds vary by cancer type, segmentation method, and study; for example, in NSCLC, MTV >30 cm³ and corresponding TLG values are associated with poorer overall survival and recurrence-free survival, with hazard ratios typically 1.5-3 in meta-analyses. These volumetric parameters stratify risk more effectively than traditional metrics, aiding in personalized prognosis and trial eligibility.^[69]^[70] Recent advances as of 2025 include AI-assisted analysis for improved tumor detection and response prediction across multiple cancer types, and expanded use of targeted tracers like PSMA for prostate cancer staging and theranostics.^[71]^[72]

Cardiology and Neurology Applications

PET–CT plays a crucial role in cardiology for evaluating myocardial viability and perfusion in patients with coronary artery disease (CAD). Using 18F-fluorodeoxyglucose (FDG), PET–CT identifies hibernating myocardium—dysfunctional but viable tissue that may recover function post-revascularization—through a perfusion-metabolism mismatch pattern, where FDG uptake remains preserved despite reduced perfusion, distinguishing it from non-viable scarred tissue.^[73] This approach has demonstrated high diagnostic accuracy, with 18F-FDG PET showing superior sensitivity and specificity compared to single-photon emission computed tomography (SPECT) and echocardiography for viability assessment in CAD patients.^[74] For myocardial perfusion imaging, rubidium-82 (Rb-82) or nitrogen-13 ammonia (N-13 ammonia) tracers are employed, achieving a sensitivity of approximately 90% in detecting ischemia, particularly in multivessel disease, due to PET's enhanced spatial resolution and ability to quantify absolute blood flow.^[75]^[76] In neurology, PET–CT aids in differentiating dementia subtypes by revealing characteristic patterns of glucose hypometabolism with 18F-FDG. In Alzheimer's disease, hypometabolism predominantly affects the temporal lobes, posterior cingulate, and precuneus, supporting early diagnosis and distinguishing it from frontotemporal dementia or dementia with Lewy bodies.^[77]^[78] For epilepsy, particularly in drug-resistant cases, interictal 18F-FDG PET–CT localizes the epileptogenic focus by identifying regional hypometabolism, often complementary to MRI, with high sensitivity for detecting focal cortical dysplasia and guiding presurgical planning.^[79] Beyond cardiology and neurology, PET–CT with 18F-FDG is valuable for detecting infection and inflammation, such as in fever of unknown origin (FUO), where it identifies occult sources like vascular infections or malignancies with a diagnostic yield of up to 75%, influencing management by localizing sites for biopsy or treatment.^[80] In musculoskeletal disorders, it excels in diagnosing osteomyelitis, providing accurate delineation of bone and soft tissue involvement with sensitivity up to 94% and specificity up to 100%, outperforming conventional imaging in chronic cases.^[81]^[82] Protocol adaptations enhance PET–CT's utility in these applications. For cardiac studies, electrocardiogram (ECG)-gated acquisitions synchronize imaging with the cardiac cycle, minimizing motion artifacts and enabling assessment of wall motion and ejection fraction alongside perfusion or viability data.^[57] In brain imaging, uptake times of 30–45 minutes post-18F-FDG injection allow optimal tracer distribution, with patients resting in a quiet environment to reduce physiological uptake variability.^[83] These applications improve clinical outcomes, particularly in guiding revascularization decisions. Viability assessment with PET–CT identifies patients likely to benefit from revascularization, with studies showing viable myocardium in about 55% of ischemic cardiomyopathy cases, leading to procedural changes in nearly 50% and associated with reduced mortality when acted upon.^[84]^[85] In perfusion imaging, quantitative flow reserve data refines ischemia risk stratification, altering management in a substantial proportion of patients by confirming or excluding the need for intervention.^[86]

Advantages and Limitations

Key Benefits

PET–CT offers enhanced diagnostic specificity compared to standalone PET or CT imaging by integrating metabolic and anatomical data, allowing for better differentiation of pathological from benign processes. For instance, the anatomical correlation provided by CT helps distinguish metabolically active tumors from inflammatory conditions like atelectasis, reducing false-positive rates. Studies have shown that this fusion can improve positive predictive value from 75% with PET alone to 89% with PET–CT, representing a notable decrease in false positives by approximately 14%.^[87]^[88]^[89] The modality streamlines clinical workflows through single-session acquisition of both PET and CT data, eliminating the need for separate visits and manual image fusion, which enhances efficiency. This integrated approach has been associated with scan time reductions of up to 23% in certain protocols, contributing to overall time savings in patient management.^[90]^[91] PET–CT provides superior quantitative capabilities by combining PET's standardized uptake value (SUV) measurements of metabolic activity with CT's density assessments, enabling precise tumor characterization and response monitoring. These metrics support accurate therapy planning, such as radiation dosimetry, by delineating active disease volumes more reliably than either modality alone.^[27]^[92]^[41] In terms of cost-effectiveness, PET–CT yields long-term savings by improving staging accuracy and avoiding unnecessary interventions, including up to an 88% reduction in surgical procedures compared to CT-based strategies. Economic analyses indicate average per-patient savings of around $13,000 through prevention of futile surgeries and reduced follow-up imaging. Meta-analyses confirm overall diagnostic accuracy gains of 15-25% over standalone PET or CT, underscoring its value in oncology management.^[93]^[94]^[91]

Challenges and Risks

One of the primary challenges in PET–CT imaging is the significant radiation exposure associated with the procedure, which combines the ionizing radiation from positron-emitting tracers in PET and X-rays in CT. A typical whole-body PET–CT scan delivers an effective dose of approximately 17.6 mSv, with cumulative doses from repeated scans posing risks for long-term health effects.^[95] Under the linear no-threshold model, this exposure is estimated to increase lifetime cancer risk by about 0.1% per 10 mSv, particularly concerning for patients requiring frequent monitoring, such as those with chronic conditions.^[96] While the diagnostic benefits often justify this risk, protocols emphasize minimizing doses through optimized tracer amounts and scan durations.^[97] PET–CT also faces technical limitations in spatial resolution, typically around 4–5 mm in modern scanners, which hinders detection of small lesions under 5 mm in diameter due to partial volume effects that blur uptake signals.^[98] This resolution constraint is exacerbated by motion artifacts, particularly respiratory motion in the lungs and cardiac motion in the heart, leading to misalignment between PET emission data and CT attenuation maps, which can distort quantification and localization of abnormalities.^[99] Such artifacts are common in thoracic imaging and may require advanced corrections like 4D gating to mitigate, though these increase scan time and complexity.^[100] Interpretation of PET–CT images presents additional challenges, as physiological FDG uptake in non-malignant tissues can mimic pathology; for instance, activated brown adipose tissue often shows intense, symmetric or asymmetric FDG avidity in the neck, supraclavicular, and paraspinal regions, potentially leading to false positives.^[101] These pitfalls necessitate experienced radiologists for accurate differentiation, as factors like cold exposure or medications can enhance such uptake, complicating oncologic assessments.^[102] Accessibility remains a barrier to widespread PET–CT use, with average scan costs ranging from $2,000 to $5,000 in the United States, influenced by facility fees, tracer production, and insurance coverage.^[103] Furthermore, the reliance on short-lived radiotracers requires proximity to cyclotrons for on-site production, limiting availability in rural areas where patients may travel hours for scans, contributing to geographic disparities in utilization.^[104] Compared to alternatives like MRI, which excels in soft tissue contrast without radiation exposure, PET–CT provides unique metabolic insights but at the expense of higher risks and costs.^[105]

Future Directions

Technological Advances

Recent advancements in PET-CT detector technology have centered on the transition from analog photomultiplier tubes to digital silicon photomultipliers (SiPMs), which offer significantly enhanced performance characteristics. Digital SiPM-based detectors provide substantial improvements in sensitivity, often around 40% or more in signal-to-noise ratio compared to traditional analog systems, primarily due to their higher photon detection efficiency and reduced noise, enabling better signal-to-noise ratios (SNR) in low-dose imaging scenarios.^[106] Additionally, the integration of depth-of-interaction (DOI) capabilities in these detectors addresses parallax errors by measuring the interaction depth of gamma photons within the scintillator crystals, thereby improving spatial resolution uniformity across the field of view and reducing distortions in off-center regions.^[107] Time-of-flight (TOF) PET has become a standard feature in new-generation systems since around 2015, leveraging precise timing measurements to localize positron annihilation events along the line-of-response. This technique enhances image SNR by a factor approximately proportional to \sqrt{d / \Delta t}, where d represents the object diameter and \Delta t is the TOF resolution, allowing for sharper images and reduced scan times even in larger patients.^[108] Parallel developments in multi-modality imaging include hybrid PET-CT-MRI systems, which combine PET's functional data with CT's anatomical detail and MRI's superior soft-tissue contrast for more comprehensive diagnostic assessments, particularly in oncology and neurology.^[109] Total-body PET-CT scanners represent a major milestone, exemplified by systems like the Siemens Biograph Vision Quadra, which extend the axial field of view to 106 cm, enabling whole-body imaging in significantly reduced times, such as a few minutes for static scans, dramatically increasing sensitivity and enabling quantitative dynamic imaging with unprecedented temporal resolution.^[110] The EXPLORER consortium's total-body scanner, with its 2018 prototype achieving first human imaging in 2019 and full clinical deployment by 2023, has further advanced this field by facilitating whole-body dynamic studies that capture rapid tracer kinetics, opening new avenues for pharmacokinetic modeling.^[111] Artificial intelligence (AI) integration is transforming PET-CT data processing, with algorithms now automating standardized uptake value (SUV) quantification and lesion detection, achieving accuracies around 90% in clinical trials for identifying metastatic sites. These AI tools, often based on deep learning models trained on large datasets, streamline workflows by reducing inter-observer variability and enhancing the precision of quantitative analyses.^[112]

Clinical and Research Trends

Recent advancements in PET–CT have expanded its role in oncology through the development of targeted radiotracers, notably prostate-specific membrane antigen (PSMA) ligands. In December 2020, the U.S. Food and Drug Administration approved [68Ga]Ga-PSMA-11 for PET imaging of PSMA-positive lesions in men with prostate cancer, enabling more precise detection of metastases compared to conventional imaging.^[113] This tracer has facilitated earlier identification of biochemical recurrence and guided treatment decisions in advanced disease.^[114] Similarly, amyloid PET tracers such as [18F]florbetapir and [18F]flutemetamol have gained prominence for tracking Alzheimer's disease progression by quantifying amyloid plaque burden longitudinally, aiding in monitoring therapeutic responses to anti-amyloid agents.^[115] In theranostics, PET–CT plays a pivotal role in selecting and monitoring patients for radioligand therapies, exemplified by [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer. Pre-therapy PSMA PET–CT identifies suitable candidates with high tumor expression, while post-therapy imaging assesses response, as demonstrated in the VISION trial where it improved overall survival by targeting PSMA-avid metastases.^[116] This approach integrates diagnostic and therapeutic functions, optimizing personalized treatment regimens and reducing off-target effects.^[117] Ongoing research emphasizes radiation dose reduction and artificial intelligence (AI) integration to enhance PET–CT's utility in personalized medicine. Ultra-low-dose protocols, leveraging advanced reconstruction algorithms, have achieved approximately 50% reductions in administered radiotracer activity without compromising diagnostic accuracy in oncologic FDG PET–CT, minimizing patient exposure while maintaining image quality.^[118] AI-driven predictive modeling, particularly deep learning on PET–CT radiomic features, enables forecasting treatment outcomes and genomic profiles in oncology, supporting tailored therapies such as immunotherapy selection.^[119] Globally, PET–CT adoption is rising in immunotherapy monitoring, with criteria like iRECIST adapted for hybrid imaging to distinguish pseudoprogression from true relapse in solid tumors, improving response evaluation in clinical trials.^[120] In pediatrics, dose adjustments based on body weight—such as nonlinear [18F]FDG regimens—have optimized imaging protocols, reducing effective doses by up to one-third over recent decades while preserving diagnostic efficacy for childhood cancers and neurological conditions.^[121] Looking ahead, PET–CT integration with genomics promises to advance precision oncology through radiogenomics, correlating imaging phenotypes with molecular data to predict tumor behavior and therapy resistance non-invasively.^[122] As of 2025, PET procedure volumes have increased by 12.2% in 2024, driven by total-body systems, with ongoing studies demonstrating further dose reductions using these scanners for applications like lymphoma therapy monitoring.^[123]^[124] In 2024-2025, advancements include AI-guided PET reconstruction enabling multi-tracer imaging and ultrafast protocols, alongside expanded theranostics applications.^[125] The global PET–CT market is projected to exceed $3 billion by 2030, driven by these innovations and expanding clinical applications.^[126]

References

[1]
PET/CT - Radiologyinfo.org
A PET scan measures important body functions, such as metabolism. It helps doctors evaluate how well organs and tissues are functioning.
[2]
Positron emission tomography scan - Mayo Clinic
Apr 16, 2025 · A positron emission tomography (PET) scan is an imaging test that can help reveal the metabolic or biochemical function of the body's tissues and organs.
[3]
Positron emission tomography: An overview - PMC - NIH
PET imaging can be also used as an effective diagnostic tool to rule out presence of metastasis in false positive cases. Breast cancer. The PET imaging has ...
[4]
Positron Emission Tomography (PET) | Johns Hopkins Medicine
Positron emission tomography (PET) is a type of nuclear medicine procedure that measures metabolic activity of the cells of body tissues.
[5]
Definition of PET-CT scan - NCI Dictionary of Cancer Terms
A PET-CT scan may be used to help diagnose disease, such as cancer, plan treatment, or find out how well treatment is working. Also called positron emission ...<|control11|><|separator|>
[6]
[PDF] PET Imaging Physics and Instrumentation - AAPM
The fundamental signal in PET results from the mutual annihilation of the positron and an electron. This results in the production of two γ rays each having ...
[7]
Introduction to PET Instrumentation | Journal of Nuclear Medicine ...
Mar 1, 2001 · The simultaneous emission of the 2 photons in opposite directions is the basis of coincidence detection and coincidence imaging. A Coincidence ...
[8]
Positron Emission Tomography - Mathematics and Physics of ... - NCBI
Efficient detection of the annihilation photons from positron emitters is usually provided by the combination of a crystal, which converts the high-energy ...
[9]
Fundamental Limits of Spatial Resolution in PET - PMC
4. Conclusions. The “fundamental” effects that limit the spatial resolution in PET cameras are the detector width, the positron range, and the acollinearity.
[10]
CT Instrumentation and Physics - StatPearls - NCBI Bookshelf
Nov 2, 2023 · [2] Hounsfield units (HU) quantify attenuation, aiding tissue characterization. However, HU values may be slightly inaccurate due to various ...
[11]
Hounsfield Scale - an overview | ScienceDirect Topics
The Hounsfield unit (HU) is defined as a quantitative scale that characterizes radiation attenuation in various tissues, assigning a value of 0 to water and ...2.2 Computed Tomography (ct) · Quantitative Imaging Of The... · Quantitative Measurements Of...
[12]
Principles of CT and CT Technology
This first article covers the fundamental principles of CT, including the basic geometry of the CT scan process, the nature of the measurements made by CT ...Principles Of Ct And Ct... · Ct Image Reconstruction · Slip Ring Scanners And...
[13]
Understanding the Standardized Uptake Value, Its Methods, and ...
Sep 1, 2004 · Somewhat analogously, in PET the standardized uptake value (SUV) came to be used as a tool to supplement visual interpretation.
[14]
Accuracy of CT-Based Attenuation Correction in PET/CT Bone Imaging
These results suggest that bias in bone uptake SUVs of PET tracers range from 2.4% to 5.9% when using CT scans at 140 and 120 kVp for attenuation correction.
[15]
X-ray-based attenuation correction for positron emission ...
A synergy of positron emission tomography (PET)/computed tomography (CT) ... The use of standardized uptake values (SUVs) is now common place in clinical ...
[16]
Combined PET/CT: the historical perspective - PMC - NIH
The proposal to combine PET with CT was made in the early 1990s by Townsend, Nutt and co-workers. The concept originated from an earlier low-cost PET ...
[17]
A Combined PET/CT Scanner for Clinical Oncology
Aug 1, 2000 · A Combined PET/CT Scanner for Clinical Oncology. Thomas Beyer, David W. Townsend ... 2000. Table of Contents · Table of Contents (PDF) · Index by ...
[18]
PET/CT Today and Tomorrow | Journal of Nuclear Medicine
Jan 1, 2004 · Since the introduction of the first PET/CT prototype in 1998 ... Ron Nutt, president of CTI Incorporated, for his friendship, insight ...
[19]
[PDF] 510(k) SUMMARY - accessdata.fda.gov
Oct 31, 2001 · The PET/CT scanner is intended to be utilized by appropriately trained health care professionals to 1) image and measure the distribution of ...
[20]
PET and CT: a perfect fit - CERN Courier
Jun 6, 2005 · After Townsend moved to Pittsburgh in 1993, his group in the US helped to develop the first combined PET/CT scanner; more than 1000 are now used ...
[21]
NCD - PET Scans (220.6) - CMS
"Any FDA-approved" means all systems approved or cleared for marketing by the Food and Drug Administration (FDA) to image radionuclides in the body. "FDA- ...
[22]
Update on Time-of-Flight PET Imaging | Journal of Nuclear Medicine
Jan 1, 2015 · The current generation of TOF PET scanners has the highest sensitivity and spatial resolution ever achieved in commercial whole-body PET.
[23]
Imaging Evolution: Hybrid PET/CT Scans
May 3, 2012 · Additional advantages include faster patient throughput; CT and PET scans can be completed in 30 to 45 minutes, whereas a PET scan alone can ...
[24]
PET Scanners Market Robust Growth with 5.9% CAGR By 2032
Dec 31, 2024 · Global Distribution: Around 2,500 PET scanners are installed globally, with an annual growth rate of about 5%. Total-Body PET Scanners ...Missing: 2020 | Show results with:2020
[25]
PET Scanning - StatPearls - NCBI Bookshelf - NIH
Feb 26, 2025 · PET scanning is an imaging technique widely used in oncology. This technique uses radiotracers to measure various metabolic processes in the body.
[26]
PET/CT Standardized Uptake Values (SUVs) in Clinical Practice and ...
The use of standardized uptake values (SUVs) is now common place in clinical FDG-PET/CT oncology imaging, and has a specific role in assessing patient response ...Missing: hybrid synergy
[27]
Role of dual PET/CT scanning in abdominal malignancies - PMC - NIH
In addition to reducing the PET imaging time per patient from 45 to 60 min with a conventional dedicated PET scanner to 15–30 min, the hybrid PET/CT scanners ...Missing: total | Show results with:total
[28]
Acquisition protocol considerations for combined PET/CT imaging
Patients can be examined with both CT and PET in a single examination. A whole-body survey is the standard mode of acquisition.
[29]
Automatic PET-CT Image Registration Method Based on Mutual ...
A new method for the registration of cardiac PET and MR images using the deformable model based on the main thorax structures. In: Niessen W, Viergever M ...
[30]
Registration of PET and CT images based on multiresolution ...
Jan 7, 2013 · In this paper, GMI demons algorithm was used to achieve local deformable registration of PET and CT images, which can effectively reduce errors ...INTRODUCTION · II. MATERIALS AND METHODS · III. RESULTS · IV. DISCUSSION
[31]
syngo Fusion Package - Siemens Healthineers USA
The syngo Fusion Package fuses previous CT, MR, or PET CT images with angio 3D or syngo DynaCT datasets, bringing other imaging modalities into the cath lab.Missing: GE | Show results with:GE
[32]
Noise reduction using a Bayesian penalized-likelihood ...
Dec 10, 2019 · The BSREM reconstruction algorithm allowed a noise reduction without a loss of contrast by a factor of 2–4 compared to OSEM reconstructions for all data ...
[33]
FDG PET/CT: EANM procedure guidelines for tumour imaging - NIH
Patients must avoid strenuous exercise for at least 6 h before the FDG PET/CT study, and preferably for 24 h. Patients should void immediately prior to the PET/ ...<|separator|>
[34]
Four‐dimensional (4D) PET/CT imaging of the thorax - Nehmeh - 2004
Nov 8, 2004 · The effect of 4D acquisition on improving the co-registration of PET and CT images, reducing motion smearing, and consequently increase the ...
[35]
State of the art in total body PET | EJNMMI Physics - SpringerOpen
May 25, 2020 · In the initial days (1980–2000), PET was a useful research tool and the real growth into clinical applications only appeared during the last 20 ...
[36]
PET/CT Image Navigation and Communication | Journal of Nuclear ...
Jan 1, 2004 · Combined PET/CT scanners provide spatially registered images from the two modalities acquired simultaneously in a single imaging session.
[37]
PET/CT Fusion Viewing Software for Use with Picture Archiving and ...
The user can navigate along dimension by interactively adjusting the degree of blending or color-overlay transparency of the functional PET data with the ...Missing: output | Show results with:output
[38]
Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0
Patients should be instructed to fast and not consume beverages, except for water, for at least 4–6 h before the administration of 18F-FDG to decrease ...<|separator|>
[39]
18F-FDG PET and PET/CT Patient Preparation
Feb 6, 2014 · Our preference is to have patients drink 1–2 L of plain water as tolerated during the 4 h immediately before the PET/CT scan.
[40]
ACR-SPR Practice parameter for Performing FDG-PET/CT in Oncology
No caffeine, alcohol, or nicotine 12 hours prior to FDG injection. Provide fasting instructions (a minimum of 4 hours) with no parenteral nutrition or oral/ ...
[41]
[PDF] Site Planning and Design of PET/CT Facilities - AAPM
Jul 26, 2007 · Patients are administered 555 MBq of F-18 FDG and there are 40 patients per week. The uptake time is 60 minutes and the imaging time is 1 hour.<|separator|>
[42]
Safety and Risk during PET Scan Exam - UC Davis Health
PREGNANCY: Please notify the Nuclear Medicine / PET physician, nurse or technologist if you are pregnant, or think you may be pregnant. Alternative imaging ...Missing: informed consent
[43]
[PDF] PET/CT FDG Scan for Patients with Diabetes - Seattle - UW Medicine
You will be fasting for a total of about 15 hours, including scan time. • If you have any questions, please call the Radiology/. Nuclear Medicine staff where ...
[44]
Determining the Minimal Required Radioactivity of 18F-FDG for ...
Mar 1, 2016 · Previous studies suggested the effective dose from PET/CT to be in the range of 10–30 mSv, depending on the activity of 18F-FDG injected (0.02 ...
[45]
[DOC] Patient's informed consent for PET/CT scanning
A serious complication that may occur during a PET/CT scan is an allergic reaction. The reaction may occur especially after intravenous administration of an ...<|control11|><|separator|>
[46]
PET and PET-CT Imaging Protocols - Radiology Key
Jul 27, 2016 · As in PET-alone imaging, the patient is positioned supine and head first on the table, except when PET-CT data are used for radiation therapy ...
[47]
Acquisition Protocol Considerations for Combined PET/CT Imaging
Jan 1, 2004 · 9B). First, a PET/CT study of the torso is performed with the patient positioned with arms up, as described in the standard whole-body protocol ...
[48]
Myocardial perfusion scintigraphy using rubidium-82 positron ...
The patient is positioned with arms above the head and is inside the scanner for the duration of the protocol, ∼30 min. Staff are outside the scan room and the ...
[49]
Gating approaches in cardiac PET imaging - PMC - NIH
In this review, we discuss recent advances in cardiac and respiratory gating and provide an overview of the most promising recent developments in the field.Missing: bellows comfort
[50]
Management of respiratory motion in PET/computed tomography - NIH
Respiratory gating is a compensation technique in which time or amplitude binning is used to exclude the motion in reconstructed PET images.Missing: ECG bellows contrast comfort
[51]
PET/CT in Oncology: Current Status and Perspectives - PMC - NIH
This review discusses the challenges and obstacles in clinical adoption of this technique. We then discuss advances in instrumentation.
[52]
Non-small cell lung cancer: prospective comparison of ... - PubMed
Integrated FDG PET/CT is significantly better than stand-alone CT for lung cancer staging and provides enhanced accuracy and specificity in nodal staging.Missing: detection | Show results with:detection
[53]
Diagnostic value of fluorine 18 fluorodeoxyglucose positron ...
Jan 15, 2013 · (18)F-FDG PET/CT confers significantly higher sensitivity and specificity than contrast-enhanced CT (both p < 0.01) and higher sensitivity than ...
[54]
Diagnostic accuracy and treatment benefit of PET/CT in staging of ...
Conclusions. PET/CT showed higher sensitivity in the detection of lymph node involvement and metastases in CRC patients compared to CT alone.
[55]
Detection of extrapulmonary lesions with integrated PET/CT in the ...
PET/CT was significantly better than CT and PET used alone. Conventional staging work-up has a poor sensitivity in detecting second primary cancers or ...
[56]
Evolving Considerations for PET Response Criteria in Solid Tumors
Statistically significant changes in tumor standardized uptake value (SUV) occur in careful test–retest studies of high-SUV tumors, with a change of 20% in SUV ...
[57]
PET/CT evaluation of response to chemotherapy in non-small cell ...
Conclusions: PERCIST and RECIST criteria have good consistency and PERCIST (or PET) is more sensitive in detecting complete remission (CR) and progression.Introduction · Methods · Results · Discussion
[58]
PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies
Nov 30, 2022 · PET-CT is an advanced imaging modality with many oncologic applications, including staging, assessment of response to therapy, restaging and evaluation of ...
[59]
Sarcoidosis mimicking lymphoma on FDG-PET imaging - PMC
Jun 19, 2011 · This study illustrated that sarcoidosis can be a pitfall in PET/CT imaging, and may lead to false-positive results of malignancy (12).
[60]
Imaging Features of Sarcoidosis on MDCT, FDG PET, and PET/CT
FDG uptake on PET in patients with sarcoidosis is nonspecific and can mimic that in malignancies such as lymphoma and diffuse metastatic disease [2].
[61]
Prognostic value of MTV and TLG of 18 F-FDG PET in patients ... - NIH
Sep 30, 2022 · The current systematic review and meta-analysis explored the value of metabolic tumor volume (MTV) as well as total lesion glycolysis (TLG) ...
[62]
Prognostic Value of Metabolic Tumor Volume and Total Lesion ...
Jun 1, 2014 · Conclusion: MTV and TLG are independent prognostic factors for predicting RFS and OS in patients with pancreatic cancer. Thus, 18F-FDG PET/CT ...
[63]
Fluorodeoxyglucose Applications in Cardiac PET: Viability ... - NIH
Mismatch pattern, which shows abnormal/reduced perfusion with normal FDG uptake; this pattern denotes hibernating myocardium and is highly likely to recover ...
[64]
Diagnostic value of 18F-FDG PET in the assessment of myocardial ...
18 F-FDG PET has high diagnostic value in the assessment of myocardial viability in patients with known CAD when compared to SPECT and echocardiography.
[65]
Diagnostic Accuracy of Rubidium-82 Myocardial Perfusion Imaging ...
In patients with single-vessel disease and multivessel (≥2-vessel) disease, rubidium-82 PET-CT had a sensitivity of 92% (22 of 24 patients, 95% CI 74% to 99%), ...
[66]
Diagnostic accuracy of 13N-ammonia myocardial perfusion imaging ...
PET-MPI with 13 N-ammonia affords high sensitivity and overall accuracy for detecting CAD. The addition of coronary artery calcium score (CACS) can improve CAD ...
[67]
Brain PET in the Diagnosis of Alzheimer's Disease - PMC - NIH
The characteristic patterns of glucose metabolism on brain FDG-PET can help in differentiating Alzheimer's disease from other causes of dementia such as ...
[68]
Brain FDG PET and the Diagnosis of Dementia | AJR
We review the role of brain FDG PET in the diagnosis of Alzheimer disease, frontotemporal dementia, dementia with Lewy bodies, and vascular dementia.
[69]
18F-FDG-PET/CT for Localizing the Epileptogenic Focus in Patients ...
Feb 3, 2024 · PET/CT is superior to MRI in detecting FCD. FCD type IIIa was more likely than other types to show MRI-/PET+. This suggests that PET/CT has particular ...
[70]
Diagnostic value of FDG-PET/CT in fever of unknown origin - PMC
Mar 1, 2022 · Fever of unknown origin is defined as a continuous or intermittent fever equal to or above 38.3 centigrade, which is there for more than 3 weeks ...
[71]
Chronic osteomyelitis: detection with FDG PET and correlation with ...
FDG PET enables noninvasive detection and demonstration of the extent of chronic osteomyelitis with a high degree of accuracy.<|separator|>
[72]
Role of 18F-FDG PET-CT in Pre-Operative Planning of Surgical ...
Nov 19, 2022 · 18F-FDG PET-CT provides a non-invasive tool for diagnosing and localizing osteomyelitis with a sensitivity reaching 94% and specificity reaching 100%.
[73]
EANM procedure guidelines for brain PET imaging using [18F]FDG ...
When static scans are acquired, patients should be positioned comfortably in a quiet, dimly lit room at least 15 min before [18F]FDG administration and during ...
[74]
Prevalence of Myocardial Viability as Detected by Positron Emission ...
Conclusions—Revascularization might improve patient prognosis in 55% and result in improved left ventricular function in 27% of all patients with ischemic ...
[75]
Impact of Positron Emission Tomography Viability Imaging - NIH
Nov 17, 2023 · Results. Viable myocardium was presented by PET imaging in 29 (54.7%) patients. Revascularization was performed in 26 (49.1%) patients, ...
[76]
18 F-FDG PET Imaging of Myocardial Viability in an Experienced ...
F-FDG PET may assist decision making in ischemic cardiomyopathy. The PET and Recovery Following Revascularization (PARR 2) trial demonstrated a trend toward ...F-Fdg Pet Imaging Of... · Materials And Methods · F-Fdg Pet--Assisted...
[77]
PET/CT and PET: Clinical value of fusion imaging in oncology
The number of false-positive findings was significantly reduced with PET/CT being its positive predictive value 89% compared with 75% for PET alone. PET-CT ...Missing: percentage | Show results with:percentage
[78]
Diagnostic Dilemma of Rounded Atelectasis in the Left Lower Lobe ...
Apr 25, 2025 · When CT findings are inconclusive, 18F-FDG-PET/CT is used to differentiate metabolically inactive rounded atelectasis from lung cancer due to ...
[79]
NCCN Task Force Report: Positron Emission Tomography (PET ...
May 1, 2007 · For example, sarcoidosis causes false-positive PET scans. Benign neoplasms and hyperplastic and dysplastic tissue may also accumulate FDG.<|separator|>
[80]
PET/CT Gating Workflow Efficiency Improvements using Continuous ...
May 1, 2015 · The average reduction of scan time when using CBM compared to SS was 23% and was statistically significant (p<0.05). Total number of clicks for ...Missing: percentage | Show results with:percentage
[81]
Monitoring Cancer Treatment with PET/CT: Does It Make a Difference?
Several studies have now indicated that for a variety of cancers, PET/CT has significantly higher staging accuracy than PET or CT alone. Perhaps most ...
[82]
A Review of PET Imaging Tracers and Methods to Incorporate PET/CT
Mar 26, 2023 · When performed properly, PET-based radiation planning can reduce treatment volumes, reduce treatment variability, improve patient and target ...<|control11|><|separator|>
[83]
Economic Evaluation of PET and PET/CT in Oncology
Moreover, CT data can be used for attenuation correction of PET data, thereby reducing the scan duration by 20%–30%. A standard examination covering the ...
[84]
PET Scanning: Worth the Cost in Cancer? Not Only Worth the Cost ...
May 15, 2014 · Through the avoidance of the costs and morbidity of unnecessary surgery, the estimated cost savings per patient was approximately $13,000.
[85]
Cumulative radiation doses from recurrent PET–CT examinations
The estimated mean effective dose for whole-body PET–CT amounted to 17.6 ± 8.7 mSv, in comparison to 3.6 ± 1.4 mSv for PET/MRI, resulting in a potential dose ...
[86]
Radiation exposure and mortality risk from CT and PET imaging of ...
The modest radiation risk that results from imaging with CT and 18 F-FDG PET can be considered as justified, but imaging should be performed with care, ...
[87]
Whole-body PET/CT scanning: estimation of radiation dose and ...
Feb 27, 2009 · Whole-body PET/CT scanning is accompanied by substantial radiation dose and cancer risk. Thus, examinations should be clinically justified, and measures should ...
[88]
Limits of Tumor Detectability in Nuclear Medicine and PET - PMC
Apr 1, 2012 · Modern clinical PET scanners have a resolution limit of 4 mm, corresponding to the detection of tumors with a volume of 0.2 ml (7 mm diameter) in 5:1 T/B ratio.
[89]
Effect of Respiratory Motion on Apparent Myocardial Uptake - PMC
There have been several studies showing that this effect can cause artifacts in PET/CT reconstructions in oncology -especially at borders between the lung and ...
[90]
4D PET/CT as a Strategy to Reduce Respiratory Motion Artifacts in ...
We describe the evidence suggesting 4D PET/CT to be one strategy to minimize the impact of respiratory motion-related image degradation on tumor target ...
[91]
Factors influencing brown fat activation in FDG PET/CT - NIH
Brown fat can exhibit high uptake of fluorine-18 fludeoxyglucose (18F-FDG) on positron emission tomography (PET) and interferes with interpretation of the scan.
[92]
Patterns of brown fat uptake of 18F-fluorodeoxyglucose in positron ...
FDG uptake is seen in brown adipose tissue in a significant number of patients. Recognizing the uptake patterns is important for optimal FDG PET interpretation.
[93]
Pet Scan Cost With Insurance - Harvard Exac
On average, the technical component can range from $500 to $3,000, while the professional component can add an additional $200 to $1,000. These costs can ...
[94]
Geographic variability in contemporary utilization of PET imaging for ...
Jul 4, 2025 · Patients in metro counties underwent PET imaging more often (8.4%) than patients in urban (7.3%) or rural counties (7.2%), p < 0.0001. At a ...
[95]
Competitive Advantage of PET/MRI - PMC - PubMed Central - NIH
PET/MRI may be preferred over PET/CT where the unique features of MRI provide more robust imaging evaluation in certain clinical settings.
[96]
A review of digital PET-CT technology - PubMed
Oct 19, 2023 · The improvement in ToF resolution and the better ToF resolution values, which result in a boost in adequate sensitivity and signal-to-noise ...
[97]
Minimizing Parallax Error in PET Detectors: Methods & Apparatus
This effect could be reduced if the depth of the interaction in the detector could be measured, which would allow a correct placement of the event and ...
[98]
Update on time-of-flight PET imaging - PMC - NIH
Dec 18, 2014 · Current generation of TOF PET scanners have the highest sensitivity and spatial resolution ever achieved in commercial whole-body PET, operate in fully-3D mode ...
[99]
PET/MRI: a novel hybrid imaging technique. Major clinical ...
PET/MRI is a promising modality for oncologic imaging of some regions, such as brain, head and neck, liver and pelvis.
[100]
Biograph Vision Quadra - Siemens Healthineers USA
Biograph Vision Quadra takes the potential of PET/CT even further. Dynamically see vertex to thighs in a single position and deepen the dimension of your
[101]
First Human Imaging Studies with the EXPLORER Total-Body PET ...
Feb 7, 2019 · Subject 2 underwent total-body PET scanning at 1, 3, 8, and 10 h after injection. At each of the 4 time points, the scan duration was 14 min.
[102]
Application of Artificial Intelligence in Oncologic Molecular PET ...
The accuracy for detecting lymph node lesions was also commendable, surpassing 90%, though the detection accuracy of local lesions was relatively low (<80%).
[103]
[PDF] Gallium Ga 68 PSMA-11 Injection, for intravenous use
Initial U.S. Approval: 2020. -------------------INDICATIONS AND USAGE ... Each patient received a single Ga 68 PSMA-11 PET/CT or. PET/MR from mid-thigh ...
[104]
PSMA PET-CT Accurately Detects Prostate Cancer Spread - NCI
May 11, 2020 · UPDATE: On December 1, 2020, the Food and Drug Administration (FDA) approved the radioactive tracer Gallium (Ga) 68 PSMA-11 for use in PET ...
[105]
Monitoring Response to Amyloid-Targeting Treatments for AD
Jul 1, 2025 · This article includes an overview of the utility of clinical assessment, amyloid PET scanning, fluid-based biomarkers, and tau and ...
[106]
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant ...
Lutetium-177 (177Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.
[107]
Prostate Cancer Theranostics With 177 Lu-PSMA - ScienceDirect.com
The FDA and EMA approved radioligand therapy using [177Lu]Lu-PSMA-617 (Lu-PSMA) for treating metastatic castration-resistant prostate cancer patients, following ...
[108]
Optimizing Oncologic FDG-PET/CT Scans | Image Wisely
The development of dual-modality positron emission tomography/computed tomography (PET/CT) systems with near-simultaneous acquisition capability has addressed ...
[109]
The Multifaceted Role of Artificial Intelligence in Enhancing ...
Jun 1, 2025 · AI models have effectively associated PET-based radiomic features with genomic data, enabling high-accuracy predictive modeling of treatment ...
[110]
Towards evidence-based response criteria for cancer immunotherapy
May 24, 2023 · A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1).
[111]
A dedicated paediatric [18F]FDG PET/CT dosage regimen - PMC - NIH
Jul 19, 2021 · Body weight has the greatest effect on [18F]FDG PET image quality in children. The proposed nonlinear dosage regimen based on body mass will ...
[112]
Insights into pet-based radiogenomics in oncology - NIH
Apr 7, 2025 · PET-based radiogenomics holds significant potential for advancing precision oncology by capturing tumor heterogeneity and improving prognostic ...
[113]
PET-CT Scanner Device Market Size Predicted to Hit USD 3.20 ...
Jun 25, 2025 · Allied Market Research has published a study report with the title PET-CT Scanner Device Market Size was Valued at USD 1.87 billion in 2020 and ...
[114]
A Vital Legacy: Biological and Environmental Research in the Atomic Age
US Department of Energy report on the history of biological and environmental research, detailing early PET developments including the 1961 Brookhaven scanner.